The Medicinal Chemistry of Novel Molecules in Clinical Trials for Tuberculosis Treatment [A Química Medicinal de Novas Moléculas em Fase Clínica para o Tratamento da Tuberculose]

Tuberculosis is a serious public health problem, especially in underdeveloped or developing countries. The first line anti-TB treatment was developed more than 40 years ago. In addition to the development of strains of Mycobacterium tuberculosis resistant to multiple drugs and co-infection with the AIDS virus, has worsened the situation of this disease worldwide. The urgent need for new therapeutic options active against multidrug-resistant strains and concurrently capable to be used with AIDS treatment has led industries, governments and nongovernmental organizations to develop new drugs. This review describes the process of developing new anti-TB drugs and the chemistry of new molecules drug candidates that are in clinical trials for this disease listed in the global portfolio of Stop TB Partnership.